Join

Compare · CRXT vs PFE

CRXT vs PFE

Side-by-side comparison of Clarus Therapeutics Holdings Inc. (CRXT) and Pfizer Inc. (PFE): market cap, price performance, sector, and recent activity on the wire.

Summary

  • Both CRXT and PFE operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
  • PFE is the larger of the two at $153.59B, about 4770.5x CRXT ($32.2M).
  • PFE has hit the wire 10 times in the past 4 weeks while CRXT has been quiet.
  • PFE has more recent analyst coverage (25 ratings vs 3 for CRXT).
MetricCRXTPFE
Company
Clarus Therapeutics Holdings Inc.
Pfizer Inc.
Price
$0.10-33.17%
$26.98+1.20%
Market cap
$32.2M
$153.59B
1M return
-
-1.21%
1Y return
-
+17.13%
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Pharmaceutical Preparations
Exchange
NASDAQ
NYSE
IPO
2021
News (4w)
0
10
Recent ratings
3
25
CRXT

Clarus Therapeutics Holdings Inc.

Clarus Therapeutics Holdings, Inc. operates as a men's health specialty pharmaceutical company that focuses on the development and commercialization of oral testosterone replacement therapy in the United States. It offers JATENZO, a soft gel oral formulation of testosterone undecanoate for treating hypogonadal men. The company has a licensing agreement with HavaH Therapeutics for product to treat androgen-dependent inflammatory breast disease and certain forms of breast cancer. Clarus Therapeutics Holdings, Inc. was founded in 2003 and is based in Northbrook, Illinois.

PFE

Pfizer Inc.

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and pain under the Eliquis, Chantix/Champix, and Premarin family brands; biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Sutent, Inlyta, Retacrit, Lorbrena, and Braftovi brands; and sterile injectable and anti-infective medicines under the Sulperazon, Medrol, Zithromax, Vfend, and Panzyga brands. The company also provides medicines and vaccines in various therapeutic areas, such as pneumococcal disease, meningococcal disease, tick-borne encephalitis, and COVID-19 under the Prevnar 13/Prevenar 13 (pediatric/adult), Nimenrix, FSME/IMMUN-TicoVac, Trumenba, and the Pfizer-BioNTech COVID-19 vaccine brands; biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, and Eucrisa/Staquis brands; and amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel/Vyndamax, BeneFIX, and Genotropin brands. In addition, the company is involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, and individual provider offices, as well as disease control and prevention centers. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Myovant Sciences Ltd.; Akcea Therapeutics, Inc; Merck KGaA; Valneva SE; BioNTech SE; and Syapse, Inc. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.

Latest CRXT

Latest PFE